Spring Bank Pharmaceuticals, which is developing a protein-modulating small molecule platform to treat viral diseases, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering.
The Milford, MA-based company, which was founded in 2002 and booked $1 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol SBPH. Spring Bank Pharmaceuticals filed confidentially on 8/3/2015. William Blair, Wedbush PacGrow and BTIG are the joint bookrunners on the deal. No pricing terms were disclosed.
